TY - JOUR
T1 - Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic
AU - Bizot, Alexandra
AU - Karimi, Maryam
AU - Rassy, Elie
AU - Heudel, Pierre Etienne
AU - Levy, Christelle
AU - Vanlemmens, Laurence
AU - Uzan, Catherine
AU - Deluche, Elise
AU - Genet, Dominique
AU - Saghatchian, Mahasti
AU - Giacchetti, Sylvie
AU - Grenier, Juline
AU - Patsouris, Anne
AU - Dieras, Véronique
AU - Pierga, Jean Yves
AU - Petit, Thierry
AU - Ladoire, Sylvain
AU - Jacot, William
AU - Benderra, Marc Antoine
AU - De Jesus, Anne
AU - Delaloge, Suzette
AU - Lambertini, Matteo
AU - Pistilli, Barbara
N1 - Funding Information:
AB, MK, ER, CL, LV, CU, ED, DG, MS, SG, JG, AP, VD, J-YP, TP, SL, WJ, M-AB, ADJ, SD: None relevant to this study. PEH reports grants, personal fees and non-financial support from PFIZER, grants and non-financial support from NOVARTIS, grants and non-financial support from ROCHE, grants, personal fees and non-financial support from AstraZeneca, personal fees and non-financial support from Mylan, grants, personal fees and non-financial support from Pierre Fabre, personal fees and nonfinancial support from AMGEN and personal fees and non-financial support from SEAGEN. ML acted as a consultant for Roche, Lilly, Novartis and AstraZeneca and received honoraria from Sandoz, Roche, Lilly, Pfizer and Novartis outside the submitted work. BP: consulting/advisor: Puma Biotechnology, Novartis, Myriad Genetics, Pierre Fabre; personal fees: Novartis, AstraZeneca, MSD Oncology, Pfizer; research funding: Daiichi-Sankyo, Puma Biotechnology, Novartis, Merus, Pfizer, AstraZeneca.
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021
Y1 - 2021
N2 - Introduction: During the COVID-19 pandemic, teleconsultation was implemented in clinical practice to limit patient exposure to COVID-19 while monitoring their treatment and follow-up. We sought to examine the satisfaction of patients with breast cancer (BC) who underwent teleconsultations during this period. Methods: Eighteen centres in France and Italy invited patients with BC who had at least one teleconsultation during the first wave of the COVID-19 pandemic to participate in a web-based survey that evaluated their satisfaction (EORTC OUT-PATSAT 35 and Telemedicine Satisfaction Questionnaire [TSQ] scores) with teleconsultation. Results: Among the 1299 participants eligible for this analysis, 53% of participants were undergoing standard post-treatment follow-up while 22 and 17% were currently receiving active anticancer therapy for metastatic and localised cancers, respectively. The mean satisfaction scores were 77.4 and 73.3 for the EORTC OUT-PATSAT 35 and TSQ scores, respectively. In all, 52.6% of participants had low/no anxiety. Multivariable analysis showed that the EORTC OUT-PATSAT 35 score correlated to age, anxiety score and teleconsultation modality. The TSQ score correlated to disease status and anxiety score. Conclusion: Patients with BC were satisfied with oncology teleconsultations during the COVID-19 pandemic. Teleconsultation may be an acceptable alternative follow-up modality in specific circumstances.
AB - Introduction: During the COVID-19 pandemic, teleconsultation was implemented in clinical practice to limit patient exposure to COVID-19 while monitoring their treatment and follow-up. We sought to examine the satisfaction of patients with breast cancer (BC) who underwent teleconsultations during this period. Methods: Eighteen centres in France and Italy invited patients with BC who had at least one teleconsultation during the first wave of the COVID-19 pandemic to participate in a web-based survey that evaluated their satisfaction (EORTC OUT-PATSAT 35 and Telemedicine Satisfaction Questionnaire [TSQ] scores) with teleconsultation. Results: Among the 1299 participants eligible for this analysis, 53% of participants were undergoing standard post-treatment follow-up while 22 and 17% were currently receiving active anticancer therapy for metastatic and localised cancers, respectively. The mean satisfaction scores were 77.4 and 73.3 for the EORTC OUT-PATSAT 35 and TSQ scores, respectively. In all, 52.6% of participants had low/no anxiety. Multivariable analysis showed that the EORTC OUT-PATSAT 35 score correlated to age, anxiety score and teleconsultation modality. The TSQ score correlated to disease status and anxiety score. Conclusion: Patients with BC were satisfied with oncology teleconsultations during the COVID-19 pandemic. Teleconsultation may be an acceptable alternative follow-up modality in specific circumstances.
UR - http://www.scopus.com/inward/record.url?scp=85116046927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116046927&partnerID=8YFLogxK
U2 - 10.1038/s41416-021-01555-y
DO - 10.1038/s41416-021-01555-y
M3 - Article
AN - SCOPUS:85116046927
VL - 125
SP - 1486
EP - 1493
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 11
ER -